Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 4 Clear all
Completed Phase 2 Interventional

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

NCT04010357
View directory record Official record
Conditions
Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions
Abemaciclib,
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 21, 2026, 8:29 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

NCT05722301
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Testosterone Therapy, No Testosterone Therapy
Drug · Other
Lead sponsor
American Hip Institute
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

NCT01073267
View directory record Official record
Conditions
Lymphoma
Interventions
TSEBT
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination

NCT04951336
View directory record Official record
Conditions
COVID-19 Vaccination
Interventions
FoTv
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 21, 2026, 8:29 AM EDT
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

NCT02293109
View directory record Official record
Conditions
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Mehrdad Abedi, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 21, 2026, 8:29 AM EDT
Recruiting Early Phase 1 Interventional

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07210632
View directory record Official record
Conditions
Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, High Grade Glioma (III or IV), High Grade Glioma (HGG) of the Brain With BRAF Aberration
Interventions
Nivolumab, Nivolumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

NCT01495793
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 21, 2026, 8:29 AM EDT
Not listed Not applicable Interventional

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

NCT00924014
View directory record Official record
Conditions
Heart Failure
Interventions
Conivaptan, Furosemide, Conivaptan and furosemide
Drug
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2009 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

NCT00536016
View directory record Official record
Conditions
Macular Degeneration
Interventions
JSM6427
Drug
Lead sponsor
Jerini Ophthalmic
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Beverly Hills, California • Boston, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 21, 2026, 8:29 AM EDT
Terminated Phase 4 Interventional Results available

High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department

NCT04398316
View directory record Official record
Conditions
Abdominal Pain, Renal Colic
Interventions
Lidocaine Iv, HYDROmorphone Injection
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

NCT00093145
View directory record Official record
Conditions
Breast Cancer
Interventions
Albumin-bound paclitaxel, Carboplatin, Herceptin®
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
14
States / cities
Long Beach, California • Stamford, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 21, 2026, 8:29 AM EDT
Recruiting Phase 2 Interventional

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

NCT05766839
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
0 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 8:29 AM EDT
Terminated Phase 1Phase 2 Interventional

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

NCT05075577
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, EPI-7386 with Enzalutamide
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 21, 2026, 8:29 AM EDT
Active, not recruiting Not applicable Interventional

Calcium Carbonate on Labor Induction

NCT06352775
View directory record Official record
Conditions
Pregnancy, Uterine Contraction
Interventions
Calcium Carbonate
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

NCT01848457
View directory record Official record
Conditions
Osteosarcoma, Nephrotoxicity, Ototoxicity
Interventions
Pantoprazole, High-dose methotrexate infusion duration
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

NCT00359619
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
CervarixTM, HPV investigational vaccine GSK568893A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 21, 2026, 8:29 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

NCT01069965
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD
Drug
Lead sponsor
N-Gene Research Laboratories, Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • Paramount, California • Tustin, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 21, 2026, 8:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT03405792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Interventions
Temozolomide (TMZ), Optune System, Pembrolizumab
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 8:29 AM EDT
Withdrawn Phase 2 Interventional

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

NCT05293509
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 8:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks

NCT07099222
View directory record Official record
Conditions
Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption, Pain After Surgery
Interventions
Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

NCT01505153
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumors
Interventions
pbi-shRNA STMN1 LP
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 21, 2026, 8:29 AM EDT
Completed Not applicable Interventional

MINDFUL-OBOT: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment

NCT03798431
View directory record Official record
Conditions
Opioid-use Disorder, Anxiety, Depression, Stress Related Disorder
Interventions
M-ROCC
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 8:29 AM EDT